Bcl-2 mRNA-targeted ribozymes: Effects on programmed cell death in chronic myelogenous leukemia cell lines

Annals of Hematology

Volumn 76, Issue 3-4, 1998, Pages 117-125

  Scheid, S ^a   Heinzinger, M ^a,b   Waller, C F ^a   Lange, W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Bcl 2; Chronic myelogenous leukemia; Programmed cell death; Ribozymes

Indexed keywords

MESSENGER RNA; OLIGONUCLEOTIDE; PROTEIN BCL 2; RIBOZYME;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL DEATH; CELL STRUCTURE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DAUDI CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA CLEAVAGE;

APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, CATALYTIC; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0031966826     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050375     Document Type: Article

References (60)

1. Wright L, Wilson SB, Milliken S, Biggs J, Kearney P (1993) Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia. Exp Hematol 21:1714-1718
2. Pyle AM (1993) Ribozymes: a distinct class of metalloenzymes. Science 261:709-714
3. Buzayan JM, McNinch JS, Schneider IR, Bruening G (1987) A nucleotide sequence rearrangement distinguishes two isolates of satellite tobacco ringspot virus RNA. Virology 160:95-99
4. Forger A, Davies C, Sheldon C, Jeffries A, Symons R (1988) Self-cleaving viroid and newt RNA may only be active as dimers. Nature 334:265-267
5. Forster A, Symons RH (1987) Self-cleavage of virusoid RNA is performed by the proposed 55. nucleotide active site. Cell 50:9-16
6. Buzayan JM, Gerlach WL, Bruening G (1986) Satellite tobacco ringspot virus RNA: a subset of the RNA sequence is sufficient for autolytic processing. Proc Natl Acad Sci USA 83:8859-3862
7. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA, Rossi JJ (1990) Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247:1222-1225
8. Kohayashi H, Dorai T, Holland JF, Ohnuma T (1993) Cleavage of human MDR1 mRNA by a hammerhead ribozyme. FEBS Lett 319:71-74
9. Lange W, Cantin EM, Finke J, Dolken G (1993) In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ ABL mRNA. Leukemia 7:1786-1794
10. Birikh KR, Heaton PA, Eckstein F (1997) The structure, function and application of the hammerhead ribozyme. Eur J Biochem 245:1-16
11. Arends MJ, Morris RG, Wyllie AH (1990) Apoptosis. The role of the endonuclease. Am J Pathol 136:593-608
12. Gorczyca W, Gong J, Darzynkiewicz Z (1993) Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 53:1945-1951
13. Rinaudo MS, Su K, Falk LA, Halder S, Mufson RA, (1995) Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells. Blood 86:80-88
14. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR (1990) Haemopoietic colony-stimulating factors promote cell survival by suppressing apoptosis. Nature 343:76-79
15. Singer GG, Carrera AC, Marshak-Rothstein A, Martinez C, Abbas AK (1994) Apoptosis. Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr Opin Immunol 6:913-920
16. Evans CA, Owen-Lynch PJ, Whetton AD, Dive C (1993) Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res 53:1735-1738
17. Cohen JJ, Duke RC, Fadok VA, Sellins KS (1992) Apoptosis and programmed cell death in immunity. Annu Rev Immunol 10:267-293
18. Nunez G, Merino R, Grillot D, Gonzalez-Garcia M (1994) Bcl-2 and Bcl-x: regulatory switches for lymphoid death and survival. Immunol Today 15:582-588
19. Williams GT (1991) Programmed cell death: apoptosis and oncogenesis. Cell 65:1097-1098
20. Dive C, Hickman JA (1991) Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 64:192-196
21. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ (1990) Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602-3610
22. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, Harris AW (1991) Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 88:8661-8665
23. Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzella F, Pierotti MA, Della Porta G (1992) bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 79:1291-1298
24. Chen-Levy Z, Nourse J, Cleary ML (1989) The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol 9:701-710
25. Vaux DL, Aguila HL, Weissman IL (1992) Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell-mediated killing. Int Immunol 4:821-824
26. Tsujimoto Y (1989) Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. Oncogene 4:1331-1336
27. Mariano MT, et al (1992) bcl-2 gene expression in hematopoietic cell differentiation. Blood 80: 768-775
28. Merino R, Ding L, Veis DJ, Korsmeyer SJ, Nunez G (1994) Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. Embo J 13:683-691
29. Fernandez-Sarabia MJ, Bischoff JR (1993) Bcl-2 associates with the ras-related protein R-ras p23. Nature 366:274-275
30. Hueber AO, Raposo G, Pierres M, He HT (1994) Thy-1 triggers mouse thymocyte apoptosis through a bcl-2-resistant mechanism. J Exp Med 179:785-796
31. Oltvai ZN, Millman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death Cell 74:609-619
32. Boise LH, et al (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608
33. Allan DJ, et al (1992) Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. J Pathol 167:25-32
34. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M (1993) Chronic myelogenous leukemia: a concise update. Blood 82:691-703
35. Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-293
36. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E (1986) Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 47:277-284
37. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233:212-214
38. Diekmann D, et al (1991) Bcr encodes a GTPase-activating protein for p21rac. Nature 351:400-402
39. van Denderen J, Hermans A, Meeuwsen T, Troelstra C, Zegers N, Boersma W, Grosveld G, van Ewijk W (1989) Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia. J Exp Med 169:87-98
40. Elefanty AG, Hariharan IK, Cory S (1990) bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. Embo J 9:1069-1078
41. Mancini M, Nanni M, Cedrone M, De Cuia MR, Rondinelli MB, Malagnino F, Alimena G (1994) Application of fluorescence in situ hybridization in defining a complex t(9;21;22) Ph formation. Haematologica (Pavia) 79:536-539
42. McGlave P (1990) Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival. Semin Hematol 27:23-30
43. Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, Thomas ED, Hansen JA (1990) Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 29:79-91
44. Lange W, Daskalakis M, Finke J, Dolken G (1994) Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs. FEBS Lett 338:175-178
45. Eaves C, Eaves A (1994) Differential manipulation of normal and chronic myeloid leukemia stem cell proliferation in vitro. Blood Cells 20:83-93
46. Cleary ML, Smith SD, Sklar J (1986) Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47:19-28
47. Campos L, Sabido O, Rouault JP, Guyotat D (1994) Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84:595-600
48. Smetsers TF, van de Locht LT, Pennings AH, Wessels HM , de Witte TM, Mensink EJ (1995) Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. Leukemia 9:118-130
49. O'Brien S, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM (1994) Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia 8:2156-2162
50. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martial P (1995) BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific hut nonantisense mechanism. Blood 86:3891-3896
51. Smetsers TF, Mensink EJ (1995) Specificity of BCR-ABL antisense oligonucleotides [letter; comment]. Blood 85:597-598
52. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F (1992) Features of apoptotic cells measured by flow cytometry. Cytometry 13:795-808
53. Smetsers TF, Skorski T, van de Locht LT, Wessels HM, Pennings AH, de Witte T, Calahretta B, Mensink EJ (1994) Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 8:129-140
54. Park JR, Bernstein ID, Hockenbery DM (1995) Primitive human hematopoietic precursors express Bcl-x hut not Bcl-2. Blood 86:868-876
55. Liu TG, Smith SW, McLaughlin KA, Schwartz LM, Osborne BA (1994) Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur 77. Nature 367:281-284
56. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR (1992) Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257:212-214
57. Allsopp TE, Wyatt S, Paterson HF, Davies AM (1993) The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell 73:295-307
58. Cuende E, Ales-Martinez JE, Ding L, Gonzalez-Garcia M, Martinez C, Nunez G (1993) Programmed cell death by bcl-2-dependent and -independent mechanisms in B lymphoma cells. Embo J 12:1555-1560
59. Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442
60. Strasser A, Harris AW, Bath ML, Cory S (1990) Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331-333